Novel preventative strategies against invasive aspergillosis

References

• Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001; 33: 1692–1696
   PubMed Web of Science ®Google Scholar
• McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 2001; 33: 641–647
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Mantadakis E, Samonis G. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect 2003; 53: 243–258
   PubMed Web of Science ®Google Scholar
• Warris A, Verweij PE. Clinical implications of environmental sources for Aspergillus. Med Mycol 2005; 43(Suppl 1)S59–S65
   Google Scholar
• Ascioglu S, de Pauw BE, Meis JF. Prophylaxis and treatment of fungal infections associated with haematological malignancies. Int J Antimicrob Agents 2000; 15: 159–168
   PubMed Web of Science ®Google Scholar
• Sherertz RJ, Belani A, Kramer BS, et al. Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med 1987; 83: 709–718
   PubMed Web of Science ®Google Scholar
• Hahn T, Cummings KM, Michalek AM, et al. Efficacy of HEPA filters in preventing aspergillosis in immunocompromised patients with hematologic malignancies. Infect Control Hosp Epidemiol 2002; 23: 525–531
   PubMed Web of Science ®Google Scholar
• Almyroudis NG, Fuller A, Jakubowski A, et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 2005; 7: 11–17
   PubMed Web of Science ®Google Scholar
• Hamza NS, Ghannoum MA, Lazarus HM. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2004; 34: 377–389
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366
   PubMed Web of Science ®Google Scholar
• Wingard JR, Leather H. A new era of antifungal therapy. Biol Blood Marrow Transplant 2004; 10: 73–90
   PubMed Web of Science ®Google Scholar
• Martino R, Subira M, Rovira M, et al. alloPBSCT Infectious/Non-infectious Complications Subcommittees of the Grupo Espanol de Trasplante Hematopoyetico (GETH). Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475–482
   PubMed Web of Science ®Google Scholar
• Thursky K, Byrnes G, Grigg A, et al. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 115–121
   PubMed Web of Science ®Google Scholar
• Prentice AG, Glasmacher A, Djulbegovic B. In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy. Br J Haematol 2006; 132: 656–659
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3597 patients. J Clin Oncol 2003; 21: 4615–4626
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Kantarjian H, O'Brien S, et al. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004; 100: 568–573
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002; 21: 161–172
   PubMed Web of Science ®Google Scholar
• Penack O, Reinwald M, Schmidt-Hieber M, , et al. Low dose liposomal amphotericin B as prophylaxis of invasive fungal infections in patients with prolonged neutropenia: results from a phase-III trial In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 16–19 December, 2005: abstract M-975 HerndonVA: ASM Press.
   Google Scholar
• Glasmacher A, Molitor E, Hahn C, et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 1998; 12: 1338–1343
   PubMed Web of Science ®Google Scholar
• Morgenstern G, Prentice AG, Prentice HG, et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 1999; 105: 901–911
   PubMed Web of Science ®Google Scholar
• Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705–713
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Cornely O, Ullmann AJ, et al. on behalf of the Itraconazole Research Group of Germany. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006; 57: 317–325
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, , et al. Posaconazole vs. fluconazole for prophylaxis of invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease: results of a multicenter trial. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 16–19 December, 2005: abstract M-716 HerndonVA: ASM Press.
   Google Scholar
• Cornely O, Maertens J, Winston D, , et al. Posaconazole vs. standard azole therapy for prophylaxis of invasive fungal infections among high-risk neutropenic patients: results of a randomized, multicenter trial. In: Program and abstracts of the 47th American Society of Hematology, Atlanta, Georgia, 10–13 December, 2005, : abstract 1844 WashingtonDC: ASM Press.
   Google Scholar
• Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006; 50: 143–147
   PubMed Web of Science ®Google Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE, et al. for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407–1416
   PubMed Web of Science ®Google Scholar
• Cornely OA, Martino R, Maschmeyer G, , et al. Efficacy of caspofungin as secondary antifungal prophylaxis for prevention of breakthrough fungal infection: data from a multinational case registry. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 16–19 December, 2005, : abstract M-957 HerndonVA: ASM Press.
   Google Scholar
• Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943–948
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Prentice AG. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother 2005; 56(Suppl 1)i23–i32
   PubMed Web of Science ®Google Scholar